Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 9/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22017356 | 0.75 | CYP2A6 (0.44) | CYP1A2CYP2A6KDM4EGPR3TRPM8 | |
| SCHEMBL12258315 | 0.64 | GPR3 (0.50) | CYP1A2CYP2A6KDM4EGPR3TRPM8 | |
| SCHEMBL13171265 | 0.62 | KDM4E (0.44) | CYP1A2CYP2A6KDM4EGPR3TRPM8 | |
| SCHEMBL21979164 | 0.61 | KDM4E (0.47) | CYP1A2CYP2A6KDM4EGPR3TSHR | |
| SCHEMBL2747868 | 0.61 | KDM4E (0.47) | CYP1A2CYP2A6KDM4EGPR3TRPM8 | |
| SCHEMBL12490240 | 0.61 | KDM4E (0.47) | CYP1A2CYP2A6KDM4EGPR3TSHR | |
| SCHEMBL19044145 | 0.61 | KDM4E (0.47) | CYP1A2CYP2A6KDM4EGPR3TRPM8 | |
| SCHEMBL12527287 | 0.60 | GPR3 (0.41) | CYP1A2CYP2A6KDM4EGPR3TRPM8 | |
| SCHEMBL12145842 | 0.59 | NPC1 (0.45) | CYP1A2CYP2A6KDM4EGPR3TSHR | |
| SCHEMBL21871920 | 0.59 | GPR3 (0.44) | CYP1A2CYP2A6KDM4EGPR3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | CYP1A2 185/4885CYP2A6 834/4885KDM4E 2522/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | CYP1A2 185/4885CYP2A6 834/4885KDM4E 2522/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | CYP1A2 185/4885CYP2A6 834/4885KDM4E 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.